Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events
26 Juni 2023 - 10:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology, non-alcoholic steatohepatitis (NASH)
and obesity, today announced that new preclinical data from a
transgenic mouse model evaluating TERN-601, the Company’s novel
oral GLP-1R agonist, were highlighted in a poster presentation at
the American Diabetes Association’s 83rd Annual Scientific
Sessions, which took place from June 23-26, 2023 in San Diego.
“We are excited by these new preclinical data shared at ADA,
which demonstrate the ability of TERN-601 to significantly improve
glucose tolerance, suppress food intake and slow gastric emptying
in transgenic mice,” said Sen Sundaram, chief executive officer at
Terns. “These data are very encouraging and support our plans to
initiate a Phase 1 first-in-human clinical trial in subjects with
an elevated body mass index in the second half of this year, with
top-line data expected in 2024.”
Humanized GLP-1R (hGLP-1R) mice were used to assess the in vivo
pharmacodynamics of TERN-601. In an intraperitoneal glucose
tolerance test, all TERN-601 doses reduced blood glucose in hGLP-1R
mice during glucose challenge. Food intake was also recorded for 24
hours in fasted mice treated with TERN-601, with food available 15
minutes post dose. TERN-601 reduced food-intake in fasted hGLPR-1R
mice. Acetaminophen (APAP) plasma levels were reduced in fasted
hGLP-1R mice administered TERN-601 four hours prior to oral
ingestion of APAP-glucose solution, indicating slowed gastric
emptying. The full poster is available on Terns’ scientific
publications website.
In addition, Terns announces that management will participate in
a Fireside Chat at the Piper Sandler Inaugural Obesity Investor Day
and will host a webinar to review Terns’ obesity franchise,
including the TERN-601 program and additional development efforts
underway in obesity.
Piper Sandler Inaugural Obesity Investor Day:
Date and Time: June 28, 2023 at 11:30 a.m. ETThe Piper Sandler
event webcast link is available from Piper Sandler and will require
registration.
Terns Obesity Franchise Webinar: Date and Time:
June 29, 2023 at 11:00 a.m. ET Webinar Link: Register
A webcast of Terns’ obesity event will be available on the
investor relations page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com. A replay of the webcast will be archived
on Terns’ website for at least 30 days following the
presentation.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to
address serious diseases, including oncology, NASH and obesity.
Terns’ pipeline includes two clinical stage development programs
including an allosteric BCR-ABL inhibitor and a THR-β agonist (+/-
an FXR agonist), and preclinical small-molecule GLP-1 receptor
agonist and GIPR modulator programs. For more information, please
visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s expectations of timing and
potential results of the clinical trials and other development
activities of the Company and its partners; the potential
indications to be targeted by the Company with its small-molecule
product candidates; the therapeutic potential of the Company’s
small-molecule product candidates; the potential for the mechanisms
of action of the Company’s product candidates to be therapeutic
targets for their targeted indications; the potential utility and
progress of the Company’s product candidates in their targeted
indications, including the clinical utility of the data from and
the endpoints used in the Company’s clinical trials; the Company’s
clinical development plans and activities, including the results of
any interactions with regulatory authorities on its programs; the
Company’s expectations regarding the profile of its product
candidates, including efficacy, tolerability, safety, metabolic
stability and pharmacokinetic profile and potential differentiation
as compared to other products or product candidates; the Company’s
plans for and ability to continue to execute on its current
development strategy, including potential combinations involving
multiple product candidates; the impact of new legislation and
regulatory developments on the Company’s plans for its product
candidates, such as the effect of the Inflation Reduction Act of
2022; and the Company’s expectations with regard to its cash runway
and sufficiency of its cash resources. All statements other than
statements of historical facts contained in this press release,
including statements regarding the Company’s strategy, future
financial condition, future operations, future trial results,
projected costs, prospects, plans, objectives of management and
expected market growth, are forward-looking statements. In some
cases, you can identify forward-looking statements by terminology
such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,”
“continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,”
“intend,” “may,” “objective,” “plan,” “positioned,” “potential,”
“predict,” “seek,” “should,” “target,” “will,” “would” and other
similar expressions that are predictions of or indicate future
events and future trends, or the negative of these terms or other
comparable terminology. The Company has based these forward-looking
statements largely on its current expectations, estimates,
forecasts and projections about future events and financial trends
that it believes may affect its financial condition, results of
operations, business strategy and financial needs. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. These statements are subject to risks and
uncertainties that could cause the actual results and the
implementation of the Company’s plans to vary materially, including
the risks associated with the initiation, cost, timing, progress,
results and utility of the Company’s current and future research
and development activities and preclinical studies and clinical
trials. These risks are not exhaustive. For a detailed discussion
of the risk factors that could affect the Company’s actual results,
please refer to the risk factors identified in the Company’s SEC
reports, including but not limited to its Annual Report on Form
10-K for the year ended December 31, 2022. Except as required by
law, the Company undertakes no obligation to update publicly any
forward-looking statements for any reason.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024